X4 pharmaceuticals, inc (XFOR)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Operating expenses:
Research and development

30,163

20,346

17,066

17,831

12,706

General and administrative

17,640

8,739

5,181

6,515

2,119

Loss on transfer of nonfinancial assets

-3,900

0

0

-

-

Total operating expenses

51,703

29,085

22,247

24,346

14,825

Loss from operations

-51,703

-29,085

-22,247

-24,346

-14,825

Other expense:
Interest income

1,197

236

64

-

-

Grant and incentive income

-

-

-

2,390

2,155

Interest expense

2,147

720

490

2,515

472

Change in fair value of preferred stock warrant liability

288

3,398

-1,360

-39

-1

Change in fair value of derivative liability

183

-89

-94

1,388

-

Other income

517

0

0

104

-77

Loss on preferred stock repurchase liability

0

0

-587

-

-

Loss on extinguishment of debt

-566

-229

0

-35

-

Total other expense, net

-1,104

-4,200

253

1,371

1,607

Net loss

-52,807

-33,285

-21,994

-22,975

-13,218

Accruing dividends on Series A convertible preferred stock

592

3,000

3,000

-

-

Adjustment to accumulated deficit in connection with repurchase of Series Seed convertible preferred stock

0

22

0

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

25

19

Net loss attributable to common stockholders

-53,399

-36,307

-24,994

-23,000

-13,237

Net loss per share attributable to common stock holders—basic and diluted (usd per share)

-4.63

-79.15

-54.58

-44.79

-26.02

Weighted average common shares outstanding—basic and diluted (in shares)

11,530

459

458

513

508

Net loss

-52,807

-33,285

-21,994

-

-

Currency translation adjustments

-119

0

0

-

-

Total comprehensive loss

-52,926

-33,285

-21,994

-

-